UCB/UCB

-0.5%
-
1D1W1MYTD1YMAX

About UCB

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Ticker

UCB

Sector

Healthcare

Trading on

BSE

Industry

Biotechnology & Drugs

CEO

Jean-Christophe Tellier

Employees

9,083

Headquarters

Anderlecht, Belgium

UCB Metrics

BasicAdvanced
€23.23B
Market cap
67.85
P/E ratio
€1.76
EPS
0.59
Beta
€0.95
Dividend rate
0.8%
Dividend yield
€23.23B
0.58725
€122.60
€65.40
315.73K
€0.95
1.317
0.922
33.382
33.85
73.47%
54.012
3.14%
2.18%
3.8%
2.67%
67.849
4.424
2.525
120.382
1.11%
0.8%
0.8%
-4.8%
-18.39%
-0.6%
-23.16%
2.31%

What the Analysts think about UCB

Analyst Ratings

Majority rating from 22 analysts.
Buy

Price Targets

Average projection from 19 analysts.
4.57% upside
High €165.00
Low €95.00
€118.85
Current price
€124.28
Average price target

UCB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.2% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€2.66B
2.86%
Net income
€32M
-89.71%
Profit margin
1.2%
-90.01%

UCB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 61.85%
QuarterlyAnnual
Q4 21
Q2 22
Q4 22
Q2 23
Q4 23
Actual
€3.09
€3.15
€1.22
€2.63
-
Expected
€2.69
€2.53
€1.02
€1.63
€1.34
Surprise
14.73%
24.75%
19.22%
61.85%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and Euronext. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for UCB stock?

UCB (UCB) has a market cap of €23.23B as of April 16, 2024.

What is the P/E ratio for UCB stock?

The price to earnings (P/E) ratio for UCB (UCB) stock is 67.85 as of April 16, 2024.

Does UCB stock pay dividends?

Yes, the UCB (UCB) stock pays dividends to shareholders. As of April 16, 2024, the dividend rate is €0.952 and the yield is 0.8%. UCB has a payout ratio of 73.47% on a trailing twelve-month basis.

When is the next UCB dividend payment date?

The next UCB (UCB) dividend payment is scheduled for April 30, 2024.

What is the beta indicator for UCB?

UCB (UCB) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the UCB stock price target?

The target price for UCB (UCB) stock is €124.28, which is 4.57% above the current price of €118.85. This is an average based on projections from 19 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell UCB stock

Buy or sell UCB stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing